Gelteq Limited (GELS)
| Market Cap | 14.25M |
| Revenue (ttm) | 98,001 |
| Net Income (ttm) | -2.37M |
| Shares Out | 9.44M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,793 |
| Open | 1.680 |
| Previous Close | 1.690 |
| Day's Range | 1.420 - 1.680 |
| 52-Week Range | 1.420 - 4.010 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2024 |
About GELS
Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia. [Read more]
Financial Performance
In 2023, Gelteq's revenue was 342,901, a decrease of -7.84% compared to the previous year's 372,071. Losses were -3.51 million, 4.08% more than in 2022.
Financial numbers in AUD Financial StatementsNews
Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white labe...
Gelteq Limited Closes US$5.2 Million Initial Public Offering
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible...
Gelteq Limited Prices US$5.2 Million Initial Public Offering
Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS” Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symb...